Literature DB >> 11032846

Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity.

F A Mercuri1, R A Maciewicz, J Tart, K Last, A J Fosang.   

Abstract

We have expressed G1-G2 mutants with amino acid changes at the DIPEN(341) downward arrow(342)FFGVG and ITEGE(373) downward arrow(374)ARGSV cleavage sites, in order to investigate the relationship between matrix metalloproteinase (MMP) and aggrecanase activities in the interglobular domain (IGD) of aggrecan. The mutation DIPEN(341) to DIGSA(341) partially blocked cleavage by MMP-13 and MMP-8 at the MMP site, while the mutation (342)FFGVG to (342)GTRVG completely blocked cleavage at this site by MMP-1, -2, -3, -7, -8, -9, -13, -14. Each of the MMP cleavage site mutants, including a four-amino acid deletion mutant lacking residues ENFF(343), were efficiently cleaved by aggrecanase, suggesting that the primary sequence at the MMP site had no effect on aggrecanase activity in the IGD. The mutation (374)ARGSV to (374)NVYSV completely blocked cleavage at the aggrecanase site by aggrecanase, MMP-8 and atrolysin C but had no effect on the ability of MMP-8 and MMP-13 to cleave at the Asn(341) downward arrowPhe bond. Susceptibility to atrolysin C cleavage at the MMP site was conferred in the DIGSA(341) mutant but absent in the wild-type, (342)GTRVG, (374)NVYSV, and deletion mutants. To further explore the relationship between MMP and aggrecanase activities, sequential digest experiments were done in which MMP degradation products were subsequently digested with aggrecanase and vice versa. Aggrecanase-derived G1 domains with ITEGE(373) C termini were viable substrates for MMPs; however, MMP-derived G2 fragments were resistant to cleavage by aggrecanase. A 10-mer peptide FVDIPENFFG, which is a substrate analogue for the MMP cleavage site, inhibited aggrecanase cleavage at the Glu(373) downward arrowAla bond. This study demonstrates that MMPs and aggrecanase have unique substrate recognition in the IGD of aggrecan and suggests that sequences at the C terminus of the DIPEN(341) G1 domain may be important for regulating aggrecanase cleavage.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032846     DOI: 10.1074/jbc.275.42.33038

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development.

Authors:  Christopher B Little; Clare T Meeker; Rosalind M Hembry; Natalie A Sims; Kate E Lawlor; Sue B Golub; Karena Last; Amanda J Fosang
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

2.  Altered endochondral bone development in matrix metalloproteinase 13-deficient mice.

Authors:  Dominique Stickens; Danielle J Behonick; Nathalie Ortega; Babette Heyer; Bettina Hartenstein; Ying Yu; Amanda J Fosang; Marina Schorpp-Kistner; Peter Angel; Zena Werb
Journal:  Development       Date:  2004-12       Impact factor: 6.868

3.  Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.

Authors:  C B Little; A Barai; D Burkhardt; S M Smith; A J Fosang; Z Werb; M Shah; E W Thompson
Journal:  Arthritis Rheum       Date:  2009-12

4.  ADAMTS4 (aggrecanase-1) cleaves human brain versican V2 at Glu405-Gln406 to generate glial hyaluronate binding protein.

Authors:  Jennifer Westling; Paul E Gottschall; Vivian P Thompson; Amber Cockburn; George Perides; Dieter R Zimmermann; John D Sandy
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

5.  Adenovirus mediated intra-articular expression of collagenase-3 (MMP-13) induces inflammatory arthritis in mice.

Authors:  K Joronen; R Ala-aho; M-L Majuri; H Alenius; V-M Kähäri; E Vuorio
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

6.  The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility.

Authors:  Bin Hu; Leopold L Kong; Russell T Matthews; Mariano S Viapiano
Journal:  J Biol Chem       Date:  2008-07-07       Impact factor: 5.157

7.  Conserved sequence in the aggrecan interglobular domain modulates cleavage by ADAMTS-4 and ADAMTS-5.

Authors:  Hazuki E Miwa; Thomas A Gerken; Tru D Huynh; Lori R Duesler; Meghan Cotter; Thomas M Hering
Journal:  Biochim Biophys Acta       Date:  2008-12-06

8.  Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair.

Authors:  Christopher B Little; Clare T Meeker; Suzanne B Golub; Kate E Lawlor; Pamela J Farmer; Susan M Smith; Amanda J Fosang
Journal:  J Clin Invest       Date:  2007-05-17       Impact factor: 14.808

9.  BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion.

Authors:  Mariano Sebastian Viapiano; Susan Hockfield; Russell Thomas Matthews
Journal:  J Neurooncol       Date:  2008-04-09       Impact factor: 4.130

10.  Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development.

Authors:  Andrew D Cook; Jarrad Pobjoy; Stefan Steidl; Manuela Dürr; Emma L Braine; Amanda L Turner; Derek C Lacey; John A Hamilton
Journal:  Arthritis Res Ther       Date:  2012-09-20       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.